Oral diseases · 2025
Prognostic Nomogram for Patients With Metastatic Tongue Squamous Cell Carcinoma: A SEER-Based Study.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yanling, Qi Zhoumiao, Hu Chaoyue, Yu Yanling, Liu Kai
Аннотация
OBJECTIVE: To construct and validate a predictive nomogram for patients with metastatic tongue squamous cell carcinoma (MTSCC).
METHODS: From 2010 to 2015, the SEER database was used to gather the clinical information of MTSCC patients. R software was used to establish a nomogram to predict the cancer-specific survival (CSS) probability of MTSCC patients. The nomogram was validated by the concordance index (C-index), the area under the receiver-operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).
RESULTS: Following screening, 284 patients were randomized, with 199 people placed in the training cohort and 85 people placed in the validation cohort, at a ratio of 7:3. By using multivariate Cox regression analysis, it was discovered that chemotherapy, lymph node dissection, brain, bone, lung metastases, and N stage were independent risk factors for CSS. The C-index was 0.664 in the training group and 0.683 in the validation group. The AUC of 1-, 3-, and 5-year CSS rates was more than 0.71, and the calibration plot further demonstrated the nomogram's strong validity. DCA showed that the nomogram had good clinical significance.
CONCLUSION: The CSS probability of patients with MTSCC can be reliably and intuitively predicted by the established nomogram model.
METHODS: From 2010 to 2015, the SEER database was used to gather the clinical information of MTSCC patients. R software was used to establish a nomogram to predict the cancer-specific survival (CSS) probability of MTSCC patients. The nomogram was validated by the concordance index (C-index), the area under the receiver-operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).
RESULTS: Following screening, 284 patients were randomized, with 199 people placed in the training cohort and 85 people placed in the validation cohort, at a ratio of 7:3. By using multivariate Cox regression analysis, it was discovered that chemotherapy, lymph node dissection, brain, bone, lung metastases, and N stage were independent risk factors for CSS. The C-index was 0.664 in the training group and 0.683 in the validation group. The AUC of 1-, 3-, and 5-year CSS rates was more than 0.71, and the calibration plot further demonstrated the nomogram's strong validity. DCA showed that the nomogram had good clinical significance.
CONCLUSION: The CSS probability of patients with MTSCC can be reliably and intuitively predicted by the established nomogram model.